article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004. One of the key priorities of the EU’s strategy is to encourage innovation to solve unmet medical needs.

article thumbnail

Uri Goren

Cadensee

When he was going through his cancer, he died in 2004. But there's a lot of other things that bother patients and might be a target for healthcare technology, or pharmaceutical products. Uri Goren: So, I guess my fascination with this came through a personal experience. So, I myself, was a care giver for my father.